- Name: Weiwei Xiao
- Title: Chief physician
- Email: xiaoww@sysucc.org.cn
- Phone:
Profile
Dr. Weiwei Xiao has been working in Sun Yat-Sen University Cancer Center since she obtained Doctor's degree in 2011. She is currently achief physician in the Department of Radiation Oncology. Her work focused on radiotherapy and research of gastrointestinal cancer, including rectal cancer, colon cancer, and anal cancer, etc. Her experience and data of anus-preserving comprehensive treatment of low rectal cancer have been included in international journals. She also presided over a number of funds such as the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province. She has published more than50 High-level Papers.
Interests
Clinical and basic research on radiation oncology of colorectal cancer and anal cancer.
Education
Sep 2001-Jun 2006 Sun Yat-sen University Bachelor degree
Sep 2006-Jun 2008 Sun Yat-sen University Master's degree
Sep 2008-Jun 2011 Sun Yat-sen University Doctor's degree
Publications
1. Xiao WW#, Chen G#, Gao YH#, Lin JZ#, Wu XJ#, Luo HL#, Lu ZH, Wang QX, Sun R, Cai PQ, Zhu CM, Liu M, Li JB, Wang YR, Jin Y, Wang F, Luo HT, Li CL, Pan ZZ*, Xu RH*. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell. 2024 Sep 9;42(9):1570-1581.e4.
2. Chen G#, Jin Y#, Guan WL#, Zhang RX#, Xiao WW#, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023 May;8(5):422-431.
3. Xie WH#, Xiao WW#, Chang H, Xu MJ, Hu YH, Zhou TC, Zhong Q, Chen CY, Lu LX, Wang QX, Zhu YJ, Yang J, Shi XY, Kang HL, Wei JW, Huang R, Peng HH, Yuan Y, Wu SH, Jiang XH, Liu YJ, Wen BX, Gao YH*. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial. BMJ. 2025 Apr 15;389:e081557.
4. Zhang ZT#, Xiao WW#, Li LR#, Wu XJ#, Wang QX#, Chang H, Tian X, Jiang W, Lin JZ, Zhang RX, Fan WH, Pan ZZ, Zhang R*, Gao YH*. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial. EClinicalMedicine. 2024 Sep 21;76:102836.
5. Hou Z#, Liao L#, Xiao W#, Sui Q, Han K, Xiao B, Li Y, Mei W, Yu J, Hong Z, Chen Q, Song R, Li D, Zhang X, Wang Q, Pan Z, Jiang W*, Ding P*. Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study. NPJ Precis Oncol. 2025 Jul 12;9(1):237.
6. Xiao W#, Luo H#, Yao Y, Wang Y, Liu S, Sun R*, Chen G*. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer. Front Immunol. 2023 Mar 24;14:1149122.
7. Xiao WW#, Yuan Y#, Wang SH#, Liao ZD, Cai PQ, Chen BQ, Zhang R, Wang F, Zeng ZF, Gao YH*. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis. Front Immunol. 2022 Jan 14;12:798451.
8. Xiao WW#, Li M#, Guo ZW#, Zhang R, Xi SY, Zhang XG, Li Y, Wu DQ, Ren YF, Pang XL, Wan XB, Li K, Zhou CL, Zhai XM, Liang ZK, Wang QX, Zeng ZF, Zhang HZ, Yang XX, Wu YS, Li M*, Gao YH*. A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):482-491.
9. Mei Y#, Xiao W#, Hu H#, Lu G#, Chen L#, Sun Z, Lü M, Ma W, Jiang T, Gao Y, Li L, Chen G, Wang Z, Li H, Wu D*, Zhou P*, Leng Q*, Jia G*. Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer. Clin Transl Med. 2021 Jun;11(6):e422.
10. Fu L#, Li S#, Xiao W#, Yu K, Li S, Yuan S, Shen J, Dong X, Fang Z, Zhang J, Chen S, Li W, You H, Xia X, Kang T, Tan J, Chen G, Yang AK*, Gao Y*, Zhou P*. DGKA Mediates Resistance to PD-1 Blockade. Cancer Immunol Res. 2021 Apr;9(4):371-385.
2. Chen G#, Jin Y#, Guan WL#, Zhang RX#, Xiao WW#, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023 May;8(5):422-431.
3. Xie WH#, Xiao WW#, Chang H, Xu MJ, Hu YH, Zhou TC, Zhong Q, Chen CY, Lu LX, Wang QX, Zhu YJ, Yang J, Shi XY, Kang HL, Wei JW, Huang R, Peng HH, Yuan Y, Wu SH, Jiang XH, Liu YJ, Wen BX, Gao YH*. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial. BMJ. 2025 Apr 15;389:e081557.
4. Zhang ZT#, Xiao WW#, Li LR#, Wu XJ#, Wang QX#, Chang H, Tian X, Jiang W, Lin JZ, Zhang RX, Fan WH, Pan ZZ, Zhang R*, Gao YH*. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial. EClinicalMedicine. 2024 Sep 21;76:102836.
5. Hou Z#, Liao L#, Xiao W#, Sui Q, Han K, Xiao B, Li Y, Mei W, Yu J, Hong Z, Chen Q, Song R, Li D, Zhang X, Wang Q, Pan Z, Jiang W*, Ding P*. Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study. NPJ Precis Oncol. 2025 Jul 12;9(1):237.
6. Xiao W#, Luo H#, Yao Y, Wang Y, Liu S, Sun R*, Chen G*. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer. Front Immunol. 2023 Mar 24;14:1149122.
7. Xiao WW#, Yuan Y#, Wang SH#, Liao ZD, Cai PQ, Chen BQ, Zhang R, Wang F, Zeng ZF, Gao YH*. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis. Front Immunol. 2022 Jan 14;12:798451.
8. Xiao WW#, Li M#, Guo ZW#, Zhang R, Xi SY, Zhang XG, Li Y, Wu DQ, Ren YF, Pang XL, Wan XB, Li K, Zhou CL, Zhai XM, Liang ZK, Wang QX, Zeng ZF, Zhang HZ, Yang XX, Wu YS, Li M*, Gao YH*. A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):482-491.
9. Mei Y#, Xiao W#, Hu H#, Lu G#, Chen L#, Sun Z, Lü M, Ma W, Jiang T, Gao Y, Li L, Chen G, Wang Z, Li H, Wu D*, Zhou P*, Leng Q*, Jia G*. Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer. Clin Transl Med. 2021 Jun;11(6):e422.
10. Fu L#, Li S#, Xiao W#, Yu K, Li S, Yuan S, Shen J, Dong X, Fang Z, Zhang J, Chen S, Li W, You H, Xia X, Kang T, Tan J, Chen G, Yang AK*, Gao Y*, Zhou P*. DGKA Mediates Resistance to PD-1 Blockade. Cancer Immunol Res. 2021 Apr;9(4):371-385.